904xrp(🥦,🥬)꩜

x.com/i/article/2050…

SACCHAROMYCES BOULARDII EVERY BENEFIT, BACKED BY A STUDY Each benefit is followed by a primary study (RCT, meta-analysis, or mechanistic paper). Where the strain matters (e.g., CNCM I-745, CNCM I-3799), the study reflects that. GUT INFECTIONS & DIARRHEA Prevents antibiotic-associated diarrhea (AAD), meta-analysis of 21 RCTs cut AAD risk from 18.7% to 8.5% (RR 0.47). pubmed.ncbi.nlm.nih.gov/26216624/ Reduces hospital-onset Clostridioides difficile infection, 48% relative risk reduction in hospitalized patients on high-risk antibiotics. academic.oup.com/cid/article/73… Inactivates C. difficile toxins A & B, the yeast secretes a 54-kDa serine protease that degrades the toxins and blocks their effects on human colonic mucosa. pmc.ncbi.nlm.nih.gov/articles/PMC96… Prevents recurrent C. difficile (especially with high-dose vancomycin), Cochrane-indexed systematic review. ncbi.nlm.nih.gov/books/NBK78217/ Adjunct to vancomycin in active CDI, 2025 RCT improves cure and reduces recurrence. nature.com/articles/s4159… Prevents traveler's diarrhea, original placebo-controlled double-blind trial (Kollaritsch 1993). pubmed.ncbi.nlm.nih.gov/8486328/ Shortens pediatric acute gastroenteritis, 2020 meta-analysis: ~1 day shorter diarrhea, higher cure rate. pubmed.ncbi.nlm.nih.gov/32056266/ Treats acute infectious diarrhea in infants, multicenter RCT of CNCM I-3799 in children 3–36 months. pubmed.ncbi.nlm.nih.gov/32796401/ Prevents enteral-nutrition (tube-feeding) diarrhea in ICU patients, multicenter RCT, 128 critically ill patients. pubmed.ncbi.nlm.nih.gov/9201523/ Resolves chronic HIV/AIDS-related diarrhea, 61% resolution on S. boulardii vs 12% on placebo. pmc.ncbi.nlm.nih.gov/articles/PMC32… H. PYLORI AND ULCERS Improves H. pylori eradication rates as adjunct to standard triple/quad therapy, meta-analysis with trial sequential analysis. pubmed.ncbi.nlm.nih.gov/31414551/ Reduces H. pylori therapy side effects (diarrhea, nausea, bloating, constipation), 2025 meta-analysis. pubmed.ncbi.nlm.nih.gov/40012609/ Improves H. pylori eradication in children, meta-analysis of pediatric RCTs. pmc.ncbi.nlm.nih.gov/articles/PMC10… IBD (CROHN'S & ULCERATIVE COLITIS) Induces clinical remission in mild-to-moderate ulcerative colitis, 17/24 patients reached remission on 750 mg/day for 4 weeks (open pilot). pubmed.ncbi.nlm.nih.gov/12840682/ Anti-inflammatory action via myeloid dendritic cells from Crohn's & UC patients, ex vivo study showing modulation of patient-derived immune cells. pubmed.ncbi.nlm.nih.gov/21903765/ Traps T cells in mesenteric lymph nodes (mechanism limiting colonic inflammation in IBD). gastrojournal.org/article/S0016-… IBS Improves IBS quality of life, RCT, all 8 IBS-QOL domains improved vs placebo (15.4% vs 7.0%). pubmed.ncbi.nlm.nih.gov/21301358/ PARASITES Treats Blastocystis hominis in children, 77.7% clinical cure with S. boulardii vs 66.6% with metronidazole vs 40% control. pubmed.ncbi.nlm.nih.gov/20922415/ Adjunct to metronidazole for Giardia lamblia, 100% cyst clearance vs 17.1% with metronidazole alone. academic.oup.com/jambio/article… SIBO Eradicates SIBO in decompensated cirrhosis, RCT: 80% SIBO clearance vs 23% placebo at 3 months. pubmed.ncbi.nlm.nih.gov/38337613/ Reduces SIBO recurrence after rifaximin, combo group 21.8% recurrence vs rifaximin alone 41.5%. pubmed.ncbi.nlm.nih.gov/40884341/ Improves SIBO in systemic sclerosis (alone or combined with metronidazole). pubmed.ncbi.nlm.nih.gov/31549334/ LIVER Reduces hepatic encephalopathy frequency in cirrhosis, secondary outcome of the cirrhosis SIBO RCT. pmc.ncbi.nlm.nih.gov/articles/PMC10… Halts NAFLD steatosis progression in humans, 90-day open trial, 250 mg x3/day. nogr.org/jour/article/v… Improves NASH (mice on methionine-choline-deficient diet), less steatosis, better liver enzymes, lower inflammation. pubmed.ncbi.nlm.nih.gov/35814685/ Mitigates fructose-induced fatty liver in rats (lipid accumulation, oxidative stress). pmc.ncbi.nlm.nih.gov/articles/PMC11… METABOLIC / OBESITY / DIABETES Reduces fat mass, hepatic steatosis, and inflammation in obese diabetic db/db mice, landmark mBio paper. pubmed.ncbi.nlm.nih.gov/24917595/ Lowers HOMA-IR and insulin levels in obese adults, 60-day double-blind RCT (S. boulardii + SOD). pmc.ncbi.nlm.nih.gov/articles/PMC84… IMMUNE & GUT BARRIER Increases secretory IgA in the small intestine, 56.9% rise in s-IgA in rat duodenal fluid. pubmed.ncbi.nlm.nih.gov/2302983/ Stimulates specific intestinal IgA response to C. difficile toxin A (4.4-fold rise in mice). pubmed.ncbi.nlm.nih.gov/11254650/ Restores tight junctions and the mucosal barrier (occludin, ZO-1, claudin-7), clinical disorders review. pubmed.ncbi.nlm.nih.gov/30804678/ Inhibits NF-kB and pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-6, IL-8), anti-inflammatory mechanism review. pmc.ncbi.nlm.nih.gov/articles/PMC27… Produces a Saccharomyces Anti-Inflammatory Factor (SAIF) that suppresses NF-kB-mediated IL-8. sciencedirect.com/science/articl… Improves sepsis-related intestinal damage by remodeling gut flora, 2025 mechanistic study. frontiersin.org/journals/cellu… ANTI-CANDIDA Inhibits Candida albicans filamentation, adhesion, and biofilm formation in vitro. pubmed.ncbi.nlm.nih.gov/19732158/ Reduces Candida translocation from the gut to lymph nodes, liver, and kidneys in immunodepressed mice. pubmed.ncbi.nlm.nih.gov/21077734/ TROPHIC / DIGESTIVE FUNCTION Boosts brush-border disaccharidase activity, sucrase +82%, lactase +77%, maltase +75%. pubmed.ncbi.nlm.nih.gov/29449779/ Activates RAS-GAP-RAF-ERK signaling in rat intestinal mucosa (mechanism behind the trophic effect). pubmed.ncbi.nlm.nih.gov/19958054/ Accelerates mucosal adaptation after intestinal resection (rats post-proximal enterectomy). pubmed.ncbi.nlm.nih.gov/10369710/ Increases fecal short-chain fatty acids (incl. butyrate) in long-term enteral nutrition patients. pubmed.ncbi.nlm.nih.gov/16273644/ CANCER / CHEMO SUPPORT Reduces irinotecan-induced intestinal mucositis and diarrhea (rat model). link.springer.com/article/10.100… Reduces abemaciclib-induced diarrhea, weight loss, and gut inflammation in rats. pmc.ncbi.nlm.nih.gov/articles/PMC10… Reduces 5-fluorouracil-induced gut inflammation and modulates TLR/MyD88/NF-kB/MAPK signaling. pubmed.ncbi.nlm.nih.gov/31401369/ Anticancer activity of S. boulardii metabolites against colon cancer cells (in vitro). pubmed.ncbi.nlm.nih.gov/36547769/ SKIN Reduces acne papules ~56% in 5 months, randomized double-blind study, 94 patients (Perenterol 100 mg or 250 mg tid). eurekamag.com/research/007/9… NOTES & CAVEATS The strongest evidence is for AAD prevention, recurrent CDI, pediatric acute diarrhea, traveler's diarrhea, and as an H. pylori eradication adjuvant, these are backed by multiple meta-analyses of human RCTs. IBD, IBS, NAFLD, T2D, acne, and anti-Candida claims rest on smaller trials, animal models, or in-vitro work. S. boulardii should not be used in critically ill or central-venous-catheter patients because of rare fungemia case reports. Most trials used CNCM I-745 (Florastor) or CNCM I-3799.